Consumer giant Kimberly-Clark has agreed to buy Kenvue, the parent company of embattled brand Tylenol, for nearly $49 billion. But what does this mean for consumers and shareholders?

Kenvue, Inc. (KVUE) has disclosed a new risk, in the Taxation & Government Incentives category. Kenvue, Inc. faces a significant risk if the ...

Yacktman Asset Management's Q3 2025 13F portfolio value declined to $7.26B, with 70 holdings and ~9% cash. Learn more about ...

The stock market marked its biggest decline in nearly a month after Wall Street shed highflying technology stocks. The S&P 500 dropped 1.2%. The Nasdaq Composite slid 2%. Both marked their biggest ...

The Kimberly-Clark/Kenvue transaction is one of the worst-received major merger deals in recent years. Investors wondered why ...

Stocks fell on Wall Street, pulled down by losses in the same big tech companies that have been the main drivers of the ...

A number of prominent hedge funds are likely applauding Monday’s news that Kimberly-Clark Corp. has agreed to acquire Kenvue ...

Potentially huge legal issues are hovering over Kenvue. But Kimberly-Clark, which agreed to buy it for $40 billion, appears ...

Kenvue’s stock, which had hit a record low in recent weeks, was headed for its best day ever, while Kimberly-Clark’s stock ...

Evercore also said Kimberly’s move expands its footprint into two stable, cash-generative global categories, personal hygiene and consumer health, that have high barriers to entry and rational pricing ...

Kimberly-Clark is buying Tylenol maker Kenvue in an approximately $48.7 billion cash-and-stock deal, creating a massive consumer health goods company ...

Asian shares have retreated despite the big lift in overseas markets from optimism over AI technology. Shares declined ...